In the phase 2 Ponatinib Ph+ ALL and CML Evaluation (PACE) trial, ponatinib, a third generation TKI with activity against unmutated and mutated BCR-ABL including the T315I mutation, demonstrated efficacy in R/R Ph+ ALL following failure of second generation TKIs [36]. This evidence concerns the gene ABL1 and acute lymphoblastic leukemia.